Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|June 21, 2007

Colorado State University Develops Tuberculosis Vaccine

A Colorado State University (Fort Collins, CO, www.colostate.edu) research team has developed a novel vaccine to prevent tuberculosis (TB).

A Colorado State University (Fort Collins, CO, www.colostate.edu) research team has developed a novel vaccine to prevent tuberculosis (TB). The vaccine triggers the body’s immunity in a novel way by activating specific immune system functions that enhance the response to the bacterium that causes tuberculosis. Although in preliminary stages of testing, the vaccine would likely be effective against all strains of TB, including multidrug and extensively drug-resistant tuberculosis. Preliminary evidence shows that the vaccine has promise of working after exposure to TB, which no other vaccine in current development has achieved. The vaccine is designed to be relatively easy to produce. Human trials for the vaccine could occur in two to three years.


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.